Pathogenesis, Intervention, and Current Status of Drug Development for Sarcopenia: A Review

被引:22
作者
Jang, Jung Yoon [1 ]
Kim, Donghwan [2 ]
Kim, Nam Deuk [1 ]
机构
[1] Pusan Natl Univ, Res Inst Drug Dev, Coll Pharm, Dept Pharm, Busan 46241, South Korea
[2] Korea Food Res Inst, Funct Food Mat Res Grp, Jeonrabug Do 55365, South Korea
关键词
sarcopenia; muscle strength; muscle atrophy; frailty; aging; senescence; skeletal muscle mass loss; intervention; clinical trials; treatment; INCLUSION-BODY MYOSITIS; MYOSTATIN ANTIBODY LY2495655; INDUCED MUSCLE ATROPHY; ASIAN WORKING GROUP; AGE-RELATED-CHANGES; SKELETAL-MUSCLE; OLDER-ADULTS; DOUBLE-BLIND; COMPUTED-TOMOGRAPHY; TRANSFORMING AGENT;
D O I
10.3390/biomedicines11061635
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Sarcopenia refers to the loss of muscle strength and mass in older individuals and is a major determinant of fall risk and impaired ability to perform activities of daily living, often leading to disability, loss of independence, and death. Owing to its impact on morbidity, mortality, and healthcare expenditure, sarcopenia in the elderly has become a major focus of research and public policy debates worldwide. Despite its clinical importance, sarcopenia remains under-recognized and poorly managed in routine clinical practice, partly owing to the lack of available diagnostic testing and uniform diagnostic criteria. Since the World Health Organization and the United States assigned a disease code for sarcopenia in 2016, countries worldwide have assigned their own disease codes for sarcopenia. However, there are currently no approved pharmacological agents for the treatment of sarcopenia; therefore, interventions for sarcopenia primarily focus on physical therapy for muscle strengthening and gait training as well as adequate protein intake. In this review, we aimed to examine the latest information on the epidemiology, molecular mechanisms, interventions, and possible treatments with new drugs for sarcopenia.
引用
收藏
页数:23
相关论文
共 212 条
[51]  
ClinicalTrials, 2016, STUD LONG TERM SAF E
[52]  
ClinicalTrials, 2016, EXT STUD EFF SAF TOL
[53]  
ClinicalTrials, 2014, STUD LY2495655 OLD P
[54]  
ClinicalTrials, 2021, ACT TREATM STUD SRK
[55]  
ClinicalTrials, STUD EV EFF SAF TALD
[56]  
ClinicalTrials, 2008, STUD GTX 024 MUSCL W
[57]  
ClinicalTrials, 2014, CLIN STUDY BYM338 TR
[58]  
ClinicalTrials, 2013, PHAS 3 STUD EFF GTX
[59]  
ClinicalTrials, 2018, DUR EXT STUD ASS CLI
[60]  
ClinicalTrials, 2018, STUD EFF SAF BIM PAT